
## marcia Hall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7199996/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genetic Alterations of Cyclins, Cyclin-Dependent Kinases, and Cdk Inhibitors in Human Cancer. Advances in Cancer Research, 1996, 68, 67-108.	5.0	646
2	Copy number signatures and mutational processes in ovarian carcinoma. Nature Genetics, 2018, 50, 1262-1270.	21.4	320
3	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncology, The, 2017, 18, 1159-1171.	10.7	293
4	Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. Journal of Clinical Oncology, 2010, 28, 3422-3428.	1.6	228
5	Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology, The, 2018, 19, 1680-1687.	10.7	187
6	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 398-411.	10.7	152
7	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet, The, 2019, 394, 2084-2095.	13.7	142
8	Neuropilin‑1 as a new potential SARS‑CoV‑2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID‑19. Molecular Medicine Reports, 2020, 22, 4221-4226.	2.4	102
9	Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study. Journal of Clinical Oncology. 2014, 32, 320-326.	1.6	99
10	An update on PARP inhibitors for the treatment of cancer. OncoTargets and Therapy, 2015, 8, 519.	2.0	72
11	ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. European Journal of Cancer, 2017, 70, 111-121.	2.8	70
12	A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive <i>TP53</i> -mutant Ovarian Cancer. Clinical Cancer Research, 2020, 26, 4767-4776.	7.0	68
13	Targeted anti-vascular therapies for ovarian cancer: current evidence. British Journal of Cancer, 2013, 108, 250-258.	6.4	64
14	British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 213, 123-139.	1.1	64
15	Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome. Annals of Surgical Oncology, 2019, 26, 2943-2951.	1.5	54
16	Identification of cancer biomarkers of prognostic value using specific gene regulatory networks (GRN): a novel role of RAD51AP1 for ovarian and lung cancers. Carcinogenesis, 2018, 39, 407-417.	2.8	38
17	Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. Clinical Cancer Research, 2019, 25, 1472-1478.	7.0	38
18	British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: Recommendations for practice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 252, 502-525.	1.1	36

marcia Hall

#	Article	IF	CITATIONS
19	Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903. Gynecologic Oncology, 2019, 154, 29-37.	1.4	35
20	Co‑expression of peripheral olfactory receptors with SARS‑CoV‑2 infection mediators: Potential implications beyond loss of smell as a COVID‑19 symptom. International Journal of Molecular Medicine, 2020, 46, 949-956.	4.0	34
21	Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 277-288.	10.7	34
22	Recurrent Ovarian Cancer: When and How to Treat. Current Oncology Reports, 2011, 13, 459-471.	4.0	28
23	Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities. Archives of Gynecology and Obstetrics, 2016, 294, 607-614.	1.7	27
24	An Unusual Case of Sex Cord Tumor With Annular Tubules With Malignant Transformation in a Patient With Peutz-Jeghers Syndrome. International Journal of Gynecological Pathology, 2010, 29, 27-32.	1.4	26
25	Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. Radiology, 2019, 293, 374-383.	7.3	25
26	Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry. International Journal of Molecular Medicine, 2019, 43, 47-56.	4.0	24
27	Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology, The, 2020, 21, 969-977.	10.7	23
28	COVIDâ€ʿ19 and SARSâ€ʿCoVâ€ʿ2 host cell entry mediators: Expression profiling of TMRSS4 in health and disease. International Journal of Molecular Medicine, 2021, 47, .	4.0	23
29	Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. International Journal of Gynecological Cancer, 2020, 30, 213-220.	2.5	22
30	Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST). Journal of Clinical Oncology, 2022, 40, 2468-2478.	1.6	22
31	The pro-social neurohormone oxytocin reverses the actions of the stress hormone cortisol in human ovarian carcinoma cells in vitro. International Journal of Oncology, 2016, 48, 1805-1814.	3.3	20
32	Kinase Inhibitors and Ovarian Cancer. Cancers, 2019, 11, 1357.	3.7	20
33	Surfactant Protein D as a Potential Biomarker and Therapeutic Target in Ovarian Cancer. Frontiers in Oncology, 2019, 9, 542.	2.8	19
34	Background and Current Treatment of Squamous Cell Carcinoma of the Anus. Oncology and Therapy, 2016, 4, 135-172.	2.6	18
35	A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 809-815.	2.3	16
36	Prognostic value of the DNA integrity index in patients with malignant lung tumors. Oncotarget, 2018, 9, 21281-21288.	1.8	16

MARCIA HALL

#	Article	IF	CITATIONS
37	A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer. Oncology Letters, 2021, 22, 650.	1.8	15
38	Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. Gynecologic Oncology, 2020, 156, 545-551.	1.4	14
39	Liquid Biopsies in Lung Cancer: Four Emerging Technologies and Potential Clinical Applications. Cancers, 2019, 11, 331.	3.7	13
40	Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. OncoTargets and Therapy, 2013, 6, 1197.	2.0	12
41	Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro. International Journal of Oncology, 2016, 49, 133-143.	3.3	12
42	Identification of Potential Bisphenol A (BPA) Exposure Biomarkers in Ovarian Cancer. Journal of Clinical Medicine, 2021, 10, 1979.	2.4	11
43	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2022, 23, 919-930.	10.7	11
44	A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol. BMC Cancer, 2014, 14, 983.	2.6	10
45	Neoadjuvant Chemotherapy without Radiation in Colorectal Cancer. Clinics in Colon and Rectal Surgery, 2020, 33, 287-297.	1.1	10
46	H2A Histone Family Member X (H2AX) Is Upregulated in Ovarian Cancer and Demonstrates Utility as a Prognostic Biomarker in Terms of Overall Survival. Journal of Clinical Medicine, 2020, 9, 2844.	2.4	10
47	Somatic Transformation in Metastatic Testicular Germ Cell Tumours – A Different Disease Entity. Anticancer Research, 2019, 39, 4911-4916.	1.1	9
48	Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: Results from a randomized, phase III, factorial trial (TRISST) Journal of Clinical Oncology, 2021, 39, 374-374.	1.6	9
49	Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours. British Journal of Cancer, 2020, 122, 483-490.	6.4	8
50	Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer. International Journal of Gynecological Cancer, 2017, 27, 1118-1122.	2.5	7
51	A Qualitative Analysis of the Impact of Carboplatin AUC 10 on Physical, Work Functioning and Bone Marrow Toxicity Among Seminoma Patients – A Single-centre Experience. In Vivo, 2019, 33, 233-237.	1.3	6
52	Identification of Cancer-Associated Circulating Cells in Anal Cancer Patients. Cancers, 2020, 12, 2229.	3.7	6
53	Reducing morbidity from insertion of chest drains. BMJ: British Medical Journal, 1997, 315, 313-313.	2.3	6
54	An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients. Ecancermedicalscience, 2016, 10, 608.	1.1	5

MARCIA HALL

#	Article	IF	CITATIONS
55	Detection of Abundant Non-Haematopoietic Circulating Cancer-Related Cells in Patients with Advanced Epithelial Ovarian Cancer. Cells, 2019, 8, 732.	4.1	5
56	Surgery for Recurrent Uterine Cancer: Surgical Outcomes and Implications for Survival—A Case Series. International Journal of Gynecological Cancer, 2017, 27, 759-767.	2.5	4
57	In Silico Study to Predict the Structural and Functional Consequences of SNPs on Biomarkers of Ovarian Cancer (OC) and BPA Exposure-Associated OC. International Journal of Molecular Sciences, 2022, 23, 1725.	4.1	4
58	Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors. International Journal of Gynecological Cancer, 2020, 30, 1026-1033.	2.5	3
59	Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status. Cells, 2021, 10, 2434.	4.1	2
60	Do Not Give Up. International Journal of Gynecological Cancer, 2017, 27, 1060-1062.	2.5	1
61	We Have the Tools: It's Time to Use Them Correctly!. Journal of Clinical Oncology, 2017, 35, 1494-1495.	1.6	1
62	Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers. In Vivo, 2020, 34, 3675-3679.	1.3	1
63	Circulating tumour cells and circulating cell-free DNA in patients with lung cancer: a comparison between thoracotomy and video-assisted thoracoscopic surgery. BMJ Open Respiratory Research, 2021, 8, e000917.	3.0	1
64	Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In Vitro. Journal of Personalized Medicine, 2022, 12, 201.	2.5	1
65	PARP inhibitors and chemoradiation for rectal cancer. The Lancet Gastroenterology and Hepatology, 2017, 2, 389-390.	8.1	0
66	Reply to "Denominator-Based Studies Need Full Disclosure of the Origins of Patients Treated― Annals of Surgical Oncology, 2019, 26, 874-875.	1.5	0